By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProQR Therapeutics B.V. 

543 Bryant Street

Palo Alto  California  94301  U.S.A.
Phone: n/a Fax: n/a



Company News
ProQR Therapeutics (PRQR) Presents In Vivo Proof Of Concept Data For The Axiomer RNA Editing Platform Technology 9/21/2017 8:11:43 AM
ProQR Therapeutics (PRQR) Receives Orphan Drug Designation From FDA For Drug Candidate QR-313 For Dystrophic Epidermolysis Bullosa And Will Present Data At Two Scientific Conferences 9/19/2017 7:39:10 AM
ProQR Therapeutics (PRQR) Spins Out CNS-Focused Biotech, Amylon Therapeutics 9/12/2017 6:15:17 AM
ProQR Therapeutics (PRQR)’s Drug Candidate QRX-421 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA 9/5/2017 7:33:23 AM
ProQR Therapeutics (PRQR) Completes Dosing Of Cystic Fibrosis Patients In QR-010 Phase Ib Trial 8/29/2017 10:22:33 AM
ProQR Therapeutics (PRQR) Strengthens Its Scientific Advisory Board With The Appointment Of Dr. Phil Zamore, Dr. Cy Stein And Dr. Scott Armstrong 8/28/2017 10:05:07 AM
ProQR Therapeutics (PRQR) Announces Results For The Second Quarter Of 2017 8/16/2017 7:10:03 AM
ProQR Therapeutics B.V. (PRQR)’s Drug Candidate QRX-411 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA 7/5/2017 9:05:54 AM
ProQR Therapeutics B.V. (PRQR) R&D Day Highlights Progress On Pipeline And Introduces Axiomer, A Novel Proprietary RNA Technology 6/15/2017 8:13:07 AM
ProQR Therapeutics B.V. (PRQR) To Present QR-010 Data At The European Cystic Fibrosis Society Conference And Provides An Update On The Ongoing Phase Ib Trial 6/8/2017 10:33:40 AM